Compare Novo Nordisk A/S (NVO) vs S&P500 ETF (SPY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs S&P500 ETF — how do they compare? Novo Nordisk A/S trades at $38.38 (market cap $165.31B), while S&P500 ETF trades at $777.52 (market cap $821.54B). The key difference: S&P500 ETF is far larger — about 5× Novo Nordisk A/S's market cap, and Novo Nordisk A/S pays a 4.71% dividend while S&P500 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and S&P500 ETF for 205 Days on average.
| NVO | SPY | |
|---|---|---|
Market Cap | $165.31B | $821.54B |
Volume | 11,432,838 | 40,070,358 |
Sector | Health | — |
52-Week High | $63.98 | $779.14 |
52-Week Low | $35.29 | $631.99 |
Typical Hold Time | 116 Days | 205 Days |
Enterprise Value | $179.56B | — |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
SPY, tracking the S&P 500, trades at $775.78, down 0.19% on the day amid a mixed technical backdrop with a bullish moving average signal but neutral oscillators. The ETF shows no available fundamental ratios in this snapshot, and a dividend of $1.89 is scheduled for payment in October 2026. Recent news highlights market volatility, with articles discussing valuation concerns and sector rotations.
The outlook for SPY hinges on broader market trends, with technical support near $771 offering a cushion. Risks include potential earnings growth slowdowns and macroeconomic pressures, but the bullish moving average alignment suggests underlying strength for long-term investors focused on U.S. equity exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →
